Yu Zhang

TL;DR: This study reveals that the novel autophagy-suppressive circPARD3 promotes LSCC progression and chemoresistance through the PRKCI-Akt-mTOR pathway, providing new insights into circRNA-mediated autophagic regulation and potential biomarker and target for LSCC treatment.

TL;DR: Mechanistic studies revealed that circCORO1C competitively bound to let-7c-5p and prevented it from decreasing the level of PBX3, which facilitated the malignant progression of LSCC and may serve as a novel target for LSCC therapy.

TL;DR: Fascin actin-bundling protein 1 (FSCN1) as discussed by the authors is a highly conserved actin bundling protein that cross links F-actin microfilaments into tight, parallel bundles and is recognized as a candidate biomarker for multiple cancer types and as a potential therapeutic target.

TL;DR: In vitro and in vivo experiments demonstrate that SKA3 promotes LSCC cell proliferation and chemoresistance through a novel role of reprogramming glycolytic metabolism, providing a potential strategy for proliferation inhibition and chemosensitization in tumors, especially for LSCC patients with PLK1 inhibitor resistance.

TL;DR: The relationship between non-coding RNAs and drug resistance of HNC is summarized, their potential clinical application in overcoming HNC chemoresistance is discussed, and they can serve as biomarkers in the diagnosis, treatment, and prognosis of H NCs.